Novartis M.S. drug shows sustained efficacy
Novartis has released impressive results from an extended Phase II study of its oral multiple sclerosis drug FTY720. Two groups taking different dosages experienced a greater than 50 percent reduction in annualized relapse rates during the first six months compared to a placebo. They maintained that rate over the next 12 months. The drug demonstrated high efficacy and tolerability levels. Standard MS treatments have relapse rates of less than 30 percent and often require frequent injections. Novartis is in a race with Serono to gain approval for the first oral M.S. drug. And analysts were clearly impressed by Novartis' prospects if it duplicates these results in a broader pivotal trial.
- read the AFX report for more information
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
